Discontinuation rates for protease inhibitor regimens containing ritonavir 600 mg versus ritonavir 400 mg plus saquinavir 400 mg

Annals of Pharmacotherapy

Volumn 33, Issue 9, 1999, Pages 899-905

  Rublein, John C ^a   Eron Jr , Joseph J ^a   Butts, John D ^a   Raasch, Ralph H ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Discontinuation; Ritonavir; Saquinavir

Indexed keywords

ABACAVIR; ANTIVIRUS AGENT; DELAVIRDINE; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DOSE TIME EFFECT RELATION; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERGLYCEMIA; LIVER FUNCTION; MAJOR CLINICAL STUDY; NEUROPATHY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEINASE INHIBITION; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; DRUG THERAPY; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL DISEASES; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NAUSEA; PROTEASE INHIBITORS; RETROSPECTIVE STUDIES; RITONAVIR; SAQUINAVIR; TREATMENT OUTCOME; VOMITING;

EID: 0032824367     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.18260     Document Type: Article

References (35)

1. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the international AIDS society-USA panel. JAMA 1998;280:78-86.
2. Anderson J, Armstead R, Baker AC, Barr D, Bozzette S, Cox S, et al. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Ann Intern Med 1998;128:1079-100.
3. Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu A, Valdes JM, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995;333:1534-9.
4. Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath C, et al. Randomized placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1998;351:543-9.
5. Moreno L, Perez-Elias MJ, Casado JL, Antela A, Munoz V, Frutos B, et al. One year experience in proteinase inhibitors use in an HIV outpatient clinic (abstract). 37th International Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON, Canada, September 28-October 1, 1997:261.
6. Merry C, Ryan M, Mulcahy F, Heavey J, Gibbons S, Barry M, et al. Tolerability of ritonavir and saquinavir during triple therapy for HIV infection (abstract). AIDS 1996;10(suppl 2):S24.
7. Kempf DJ, Marsh KC, Kumar G, Rodrigues AD, Denissen JF, McDonald E, et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 1997;41:654-60.
8. Merry C, Barry MG, Mulcahy F, Ryan M, Heavey J, Tjia JF, et al. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997;11:F29-33.
9. Schapiro JM, Winters MA, Stewart F, Efron B, Norris J, Kozal MJ, et al. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med 1996;124:1039-50.
10. Vanhove GF, Gries JM, Verotta D, Sheiner LB, Coombs R, Collier AC, et al. Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy. Antimicrob Agents Chemother 1997; 41:2433-8.
11. Talal A, Cao Y, Hurley A, Schluger R, Fischer L, Salgo M, et al. Saquinavir in combination with AZT/3TC and ritonavir: a convenient BID regimen (abstract). 37th International Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON, Canada, September 28-October 1, 1997:282.
12. Henry K, Kane E, Melroe H, Simpson J, Patick A, Winslow D. Experience with a ritonavir/saquinavir based regimen for the treatment of HIV-infection in subjects developing increased viral loads while receiving nelfinavir (abstract). 37th International Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON, Canada, September 28-October 1, 1997:282.
13. Michelet C, Bellissant E, Delfraissy JF, Arvieux C, Ruffault A, Stagnetto C, et al. Safety and efficacy of a combination of ritonavir and saquinavir added to AZT + 3TC in HIV infected patients (abstract). 37th International Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON, Canada, September 28-October 1, 1997:281.
14. Farthing C, Japour A, Cohen C, Cameron W, Follansbee S, Markowitz M, et al. Cerebrospinal fluid and plasma HIV RNA suppression with ritonavir-saquinavir in protease inhibitor naïve patients (abstract). 37th International Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON, Canada, September 28-October 1, 1997:8 (program addendum).
15. Battegay M, Bernasconi E, Flepp M, Vernazza P, Malinverni R, Zanetti G, et al. A pilot study of saquinavir in combination with ritonavir and d4T in patients with advanced HIV disease (abstract). 37th International Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON, Canada, September 28-October 1, 1997:281.
16. Rhone SA, Hogg RS, Yip B, Sherlock C, Conway B, Schechter MT, et al. The antiviral effect of ritonavir and saquinavir in combination amongst HIV infected adults: results from a community based study. AIDS 1998; 12:619-24.
17. Lorenzi P, Yerly S, Abderrakim K, Fathi M, Rutschmann OT, von Overbeck J, et al. Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. AIDS 1997;11:F95-9.
18. Merry C, Barry M, Gibbons S, Mulcahy F, Back D. Improved tolerability of ritonavir derived from pharmacokinetic principles (letter). Br J Clin Pharmacol 1996;42:787.
19. Prescribing information. Norvir (ritonavir capsules) (ritonavir oral solution). Chicago, IL: Abbott Laboratories, March 1997.
20. Keruly JC, Chaisson RE, Moore RD. Diabetes and hyperglycemia in patients receiving protease inhibitors (abstract). 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998:157.
21. Dong BJ, Gruta C, Legg J, Balano K, Goldschmit RH. Diabetes and use of protease inhibitors (abstract). 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998:157.
22. Antela A, Perez-Elias MJ, Casado JL, Dronda F, Sabido R, Moreno L, et al. Ritonavir + saquinavir as a rescue therapy after indinavir failure (abstract). 12th World AIDS Conference, Geneva, Switzerland, June 28-July 3, 1998.
23. Batisse D, Salmon-Seron D, Karmochkine M, Ginsburg C, Castiel P, Raguin G, et al. Efficacy and safety of ritonavir and saquinavir in combination in protease inhibitors-experienced patients (abstract). 37th International Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON, Canada, September 28-October 1, 1997:282.
24. Cavorus A, Thompson CE, Salvato PD. Salvage therapy for antiretroviral failure in HIV+ patients (abstract). 12th World AIDS Conference, Geneva, Switzerland, June 28-July 3, 1998.
25. Deeks SG, Grant RM, Beatty GW, Horton C, Detmer J, Eastman S. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure. AIDS 1998;12:F97-102.
26. Gallant JE, Barnett S, Raines C, Hall C. Efficacy and durability of ritonavir/saquinavir as salvage therapy after failure of initial protease inhibitor regimen (abstract). 12th World AIDS Conference, Geneva, Switzerland, June 28-July 3, 1998.
27. Puig T, Bonjoch A, Ruiz L, Arno A, Sirera G, Romeu J, et al. Usefulness of ritonavir and saquinavir combination therapy for HIV-advanced patients failing on indinavir (abstract). 37th International Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON, Canada, September 28-October 1, 1997:281.
28. Rodriguez-Rosado R, Soriano V, Jimenez I, Anton P, Gonzalea-Lahoz J. Efficacy and safety of the combination of ritonavir plus saquinavir, with two nucleoside analogues (abstract). 12th World AIDS Conference, Geneva, Switzerland, June 28-July 3, 1998.
29. Scerpella E, Moreno JN, Dashefsky M, Jayaweera DT, Boulanger C, Rodriguez AE. Ritonavir + saquinavir salvage therapy in antiretroviral-experienced patients (abstract). 12th World AIDS Conference, Geneva, Switzerland, June 28-July 3, 1998.
30. Tebas P, Patick AK, Kane E, Klebert M, Simpson J, Atkinson B, et al. 60 week virologic responses to a ritonavir/saquinavir containing regimen in patients who had previously failed nelfinavir (abstract). 6th Conference on Retroviruses and Opportunistic Infections, Chicago, January 31-February 4, 1999.
31. Farthing C, Mess T, Ried C, Radhakrishna S, Wallace M. Ritonavir, saquinavir, and nevirapine as a salvage regimen for indinavir or ritonavir resistance (abstract). 12th World AIDS Conference, Geneva, Switzerland, June 28-July 3, 1998.
32. Ruane PJ, Tam JT, Libraty DH, Sokolov RT, Uman SJ, Zakowski PC. Salvage therapy using ritonavir/saquinavir with a non-nucleoside reverse transcriptase inhibitor after prolonged failure with indinavir or ritonavir (abstract). 12th World AIDS Conference, Geneva, Switzerland, June 28-July 3, 1998.
33. Kaufmann G, Duncombe C, Beveridge A, Chuah J, Carr A, Cunningham P, et al. Efficacy of a four drug combination therapy including two protease inhibitors in patients with advanced HIV-1 illness (abstract). 37th International Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON, Canada, September 28-October 1, 1997:281.
34. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nautre 1995;374:569-71.
35. Condra JH, Holder DJ, Schleif WA, Blahy OM, Danovich RM, Gabryelski LJ, et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996; 70:8270-6.